HCAT vs HIMS Stock Comparison
Compare HCAT and HIMS across AIQ Score, fundamentals, valuation, momentum, risk, analyst expectations and current market evidence.
What is the main difference between HCAT and HIMS?
HCAT leads the current stock comparison as Health Catalyst, Inc., with the clearest separation coming from momentum and the broader AIQ evidence mix.
AlgovestIQ AIQ Comparison
Health Catalyst, Inc. vs Hims & Hers Health, Inc.
HCAT leads
HCAT leads by 13 AIQ points, primarily on Momentum and Risk Resilience, and the lead has widened from 0 points over 30 sessions.
Stable: 4 of 6 evidence groups support HCAT, its lead is widening, and its signal state is cleanly positive.
Health Catalyst, Inc.
Hims & Hers Health, Inc.
The Algovestiq AIQ Score currently favors HCAT over HIMS, 49 versus 36 as of Sep 11, 2026. HCAT's advantage is driven primarily by stronger momentum and risk resilience. HCAT also shows the weaker technical structure relative to its 50-day moving average. 4 of 6 covered evidence groups favor HCAT today, and the comparison is rated Stable on stability: analyst targets on the leader are widely dispersed. HCAT lead: Strengthening — the AIQ differential moved from 0 to 13 points over 30 sessions.
Compare Health Catalyst, Inc. and Hims & Hers Health, Inc. across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.
Performance over time
Price-return comparison using available daily close history.
Total return comparison
Growth of $10,000
Based on available close-price history. Distribution reinvestment is not added unless already reflected in the source series.
Compare HCAT and HIMS against another ticker
Open a multi-ticker workspace without changing this focused pair page.
AIQ Factor Divergence
Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.
- Momentum52 vs 29HCAT +23
- Risk Resilience39 vs 19HCAT +20
- Value73 vs 58HCAT +15
- Quality26 vs 29Even
4 of 6 evidence groups favor HCAT. HCAT’s edge is concentrated in momentum and risk resilience.
What changed since the last close
Latest scored session 2026-09-10, compared against the prior scored session 2026-09-09.
Largest factor move: Momentum +7
No new signals fired.
Largest factor move: Momentum -4
No new signals fired.
HCAT's lead widened by 3 AIQ points in the latest snapshot.
Deeper signal detail for each name lives on its own signals page — HCAT and HIMS both carry a full feed there.
The central trade-off
HCAT (Health Catalyst, Inc.): the stronger current systematic profile, led by momentum and risk resilience.
HIMS (Hims & Hers Health, Inc.): the counter-case, on fundamentals, technicals — but at materially higher volatility, 83.4% against 52.4%.
Which one fits your objective
The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.
Balanced
HCATHCAT on the overall AIQ Score, which weights Quality and Value most heavily.
Growth
HCATHCAT on combined revenue and EPS growth.
Value
HCATHCAT on the peer-relative Value factor, by 15 points.
Momentum
HCATHCAT on the Momentum factor, by 23 points.
Lower downside
HCATHCAT on Risk Resilience, by 20 points.
Analyst upside
HCATHCAT on implied upside to the consensus price target.
AIQ vs Wall Street
Where the systematic read and the analyst consensus line up — and where they do not.
| Measure | HCAT | HIMS | Note |
|---|---|---|---|
| Implied upside to target | +22.4% | +13.5% | HCAT has more room |
| Target dispersion | +60.1% | +60.8% | Lower is tighter analyst agreement |
| Consensus | Hold | Hold | Context, not a primary driver |
| Analysts covering | 3 | 9 | Higher coverage generally improves confidence |
Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.
AIQ Agreement Matrix
4 of 6 covered evidence groups favor HCAT. A wide gap backed by one group is a weaker case than a narrow gap backed by five.
| Evidence group | Favors | Reading |
|---|---|---|
| AIQ Score | HCAT | 49 vs 36 |
| Fundamentals | HIMSon balance | EPS growth 64.1% vs 7.5%; TTM ROE -129.7% vs -30%; gross margin 46.4% vs 64.7%; operating margin -19.7% vs -3.6% — HIMS takes 3 of 4 decided legs, not all of them |
| Valuation | HCAT | Value 73 vs 58 |
| Technicals | HIMS | Price vs 50-day -12.8% vs -11.9%; vs 200-day -6.6% vs -2.9% |
| Risk Resilience | HCAT | Risk Resilience 39 vs 19 |
| Analyst expectations | HCAT | Target upside 22.4% vs 13.5% |
✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of HCAT and HIMS and are excluded from the count.
AIQ Decision Stability
The conclusion rests on a wide gap and broad agreement. It is unlikely to turn on a single session.
- The AIQ gap is wide at 13 points. (supports the conclusion holding)
- The leader's advantage has been widening. (supports the conclusion holding)
- The leader's signal state is cleanly positive. (supports the conclusion holding)
- Analyst targets on the leader are widely dispersed. (argues the conclusion is provisional)
Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on HCAT.
How the comparison changed
119 daily snapshots · May 4 – Sep 10HCAT lead: Strengthening — the AIQ differential moved from 0 to 13 points over 30 sessions.
- Today
- HCAT +13
- 49 vs 36
- 7 sessions ago
- HCAT +7
- 46 vs 39
- 30 sessions ago
- Level
- 43 vs 43
- 90 sessions ago
- HCAT +7
- 55 vs 48
The lead changed hands 3 times in this window, most recently on Aug 24 when HCAT moved ahead of HIMS.
AIQ Signal Divergence
Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.
2 bullish / 0 bearish / 1 neutral
- Golden Cross Active — bullish, trend, long horizon (5.20%)
- ATR Expansion - Breakout Mode — neutral, volatility, short horizon (6.40%)
- MACD Bullish Crossover — bullish, momentum, short horizon
1 bullish / 1 bearish / 2 neutral, conflicted
- Golden Cross Active — bullish, trend, long horizon (10.51%)
- Bollinger Band Squeeze — neutral, volatility, short horizon
- ATR Expansion - Breakout Mode — neutral, volatility, short horizon (6.59%)
HIMS is conflicted, so the timing case there is weaker than the score alone suggests.
Price vs model alignment
Whether the latest session's price move confirms what the model did over the same session, or contradicts it.
Price is down while the AIQ Score moved up 2 points over the same session — price and model disagree (price -1.73%, AIQ +2 points).
Price is up while the AIQ Score moved down 1 points over the same session — price and model disagree (price +0.26%, AIQ -1 points).
What would flip this result
A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.
- 1HIMS closes the Momentum gap — currently 23 points behind, the largest single contributor to HCAT's edge.
- 2HIMS's Bollinger Band Squeeze turns directional — it is neutral today and would confirm a change in trend.
- 3HCAT's Golden Cross Active breaks down — it is the strongest rule currently supporting the verdict.
- 4A regime shift changes factor weighting — Quality and Value carry the heaviest weights in the composite, so a rotation toward either would move the result most.
The full evidence
Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.
Fundamentals
HIMS leads on balance| Metric | HCAT | HIMS |
|---|---|---|
| Revenue growth (YoY) | -0.4% | 23.9% |
| EPS growth (YoY) | 64.1% | 7.5% |
| Gross margin | 46.4% | 64.7% |
| Operating margin | -19.7% | -3.6% |
| Return on equity (TTM) | -129.7% | -30% |
| Debt to equity | 1.69 | 4.77 |
Performance
Split across windows| Metric | HCAT | HIMS |
|---|---|---|
| 1 week (5 sessions) | 2.4% | -4.3% |
| 1 month (20 sessions) | -3.4% | -8.4% |
| 3 months (63 sessions) | 8.1% | -1.2% |
| 6 months (126 sessions) | -7% | 6% |
| Year to date | -27.6% | -15.5% |
| 1 year (252 sessions) | -48.8% | -44.7% |
Technicals
HIMS has the stronger structure| Metric | HCAT | HIMS |
|---|---|---|
| RSI (14) | 62.5 | 36.3 |
| ADX (14) | 18.8 | 11.9 |
| Price vs 50-day | -12.8% | -11.9% |
| Price vs 200-day | -6.6% | -2.9% |
| Volatility (1M, annualized) | 52.4% | 83.4% |
Risk
HCAT is the more resilient| Metric | HCAT | HIMS |
|---|---|---|
| Beta | 1.34 | 2.76 |
| Sharpe ratio | -0.36 | -0.19 |
| Sortino ratio | -0.57 | -0.34 |
| Max drawdown | -70.7% | -76.9% |
| Current drawdown | -49.1% | -56.3% |
| Annualized volatility | 90% | 93.2% |
| Value at risk (95%) | -6.9% | -7.9% |
Straight answers
Each answer is regenerated from the current snapshot, not written once and left to age.
Which is better, HCAT or HIMS?
On the Algovestiq AIQ Score, HCAT is the stronger of the two as of Sep 11, 2026, scoring 49 against HIMS's 36. The edge comes from momentum and risk resilience. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.
Is HCAT or HIMS the better buy right now?
HCAT carries the stronger systematic profile as of Sep 11, 2026, and the comparison is rated Stable — 4 of 6 covered evidence groups agree. A Stable rating means the gap is wide and the evidence is broad, so the conclusion is unlikely to turn on a single session.
Why does the AIQ Score favor HCAT over HIMS?
The composite weights Quality, Value, Momentum and Risk Resilience. HCAT leads Momentum by 23 points; HCAT leads Risk Resilience by 20 points; HCAT leads Value by 15 points. Where the two split, the factor with the larger weight carries the result.
Which has more analyst upside, HCAT or HIMS?
Analyst price targets imply +22.4% upside for HCAT and +13.5% for HIMS, so the Street currently favors HCAT. The model and the Street agree here, which is a broader base of evidence than either alone. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.
Which is better value, HCAT or HIMS?
HCAT is the better-valued of the two on the peer-relative Value factor. HCAT on the peer-relative Value factor, by 15 points. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.
Which has stronger growth, HCAT or HIMS?
HCAT on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.
Which has stronger momentum, HCAT or HIMS?
HCAT on the Momentum factor, by 23 points. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.
Which is riskier, HCAT or HIMS?
HCAT is the more resilient of the two, so the other name carries the higher downside risk. HCAT on Risk Resilience, by 20 points. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.
Is HCAT more profitable than HIMS?
HIMS leads on the comparable margin measures — gross margin 46.4% vs 64.7%; operating margin -19.7% vs -3.6%; ttm roe -129.7% vs -30%.
Is HCAT's lead over HIMS getting stronger or weaker?
HCAT lead: Strengthening — the AIQ differential moved from 0 to 13 points over 30 sessions. This is measured from 119 daily comparison snapshots between 2026-05-04 and 2026-09-10. The lead has changed hands 3 times in that window, most recently on 2026-08-24, when HCAT moved ahead of HIMS.
What would change the HCAT vs HIMS verdict?
The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: HIMS closes the Momentum gap — currently 23 points behind, the largest single contributor to HCAT's edge; HIMS's Bollinger Band Squeeze turns directional — it is neutral today and would confirm a change in trend; HCAT's Golden Cross Active breaks down — it is the strongest rule currently supporting the verdict; a regime shift changes factor weighting — Quality and Value carry the heaviest weights in the composite, so a rotation toward either would move the result most.
What do the current signals say about HCAT and HIMS?
HCAT: 2 bullish / 0 bearish / 1 neutral. HIMS: 1 bullish / 1 bearish / 2 neutral, conflicted. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on HCAT is Golden Cross Active (bullish, long horizon). On HIMS it is Golden Cross Active (bullish, long horizon).
Compare HCAT and HIMS with others
Continue your research
This page answers which of the two. These answer the questions on either side of it.
How this comparison is scored
The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.
The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.
How to use side-by-side comparison →This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.